Fear
1
Pipeline Programs
2
Companies
4
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Angeles TherapeuticsCA - Los Angeles
4 programs1
NaltrexonePhase 11 trial
Deep Brain StimulationN/A
Social SupportN/A1 trial
Social support imageN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Angeles TherapeuticsNaltrexone
Angeles TherapeuticsSocial support image
Angeles TherapeuticsSocial Support
NeuroPaceDeep Brain Stimulation
Clinical Trials (4)
Total enrollment: 340 patients across 4 trials
Opioids and Social Support Enhanced Extinction Effects
Start: Dec 2021Est. completion: Dec 202660 patients
Phase 1Enrolling By Invitation
Social Support and Reduced Fear Acquisition
Start: Feb 2022Est. completion: Nov 2026100 patients
N/AActive Not Recruiting
Social Support and Enhanced Fear Extinction
Start: Feb 2022Est. completion: Dec 2026100 patients
N/AActive Not Recruiting
Intracranial Neurophysiological Signatures of Fear and Anxiety in Humans
Start: Oct 2021Est. completion: May 202780 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 340 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.